Literature DB >> 28349817

Salinomycin: A new paradigm in cancer therapy.

Jayant Dewangan1, Sonal Srivastava1, Srikanta Kumar Rath1.   

Abstract

The primary hurdle in the treatment of cancer is acquisition of resistance by the tumor cells toward multiple drugs and selectively targeting the cancer stem cells. This problem was overcome by the chemotherapeutic property of recently discovered drug salinomycin. Exact mechanism of action of salinomycin is not yet known, but there are multiple pathways by which salinomycin inhibits tumor growth. Salinomycin decreases the expression of adenosine triphosphate-binding cassette transporter in multidrug resistance cells and interferes with Akt signaling pathway, Wnt/β-catenin, Hedgehog, and Notch pathways of cancer progression. Salinomycin selectively targets cancer stem cells. The potential of salinomycin to eliminate both cancer stem cells and therapy-resistant cancer cells may characterize the compound as a novel and an efficient chemotherapeutic drug.

Entities:  

Keywords:  Salinomycin; cancer; cancer stem cells; multidrug resistance

Mesh:

Substances:

Year:  2017        PMID: 28349817     DOI: 10.1177/1010428317695035

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

Review 1.  p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy.

Authors:  Christie Rodriguez-Ramirez; Jacques E Nör
Journal:  Crit Rev Oncog       Date:  2018

2.  Combined Strategy of Radioactive 125I Seeds and Salinomycin for Enhanced Glioma Chemo-radiotherapy: Evidences for ROS-Mediated Apoptosis and Signaling Crosstalk.

Authors:  Chao Liu; Ligang Wang; Hongmei Qiu; Qing Dong; Yong Feng; Dawei Li; Chengli Li; Cundong Fan
Journal:  Neurochem Res       Date:  2018-05-26       Impact factor: 3.996

Review 3.  The complex relationship between multiple drug resistance and the tumor pH gradient: a review.

Authors:  Tomas Koltai
Journal:  Cancer Drug Resist       Date:  2022-04-03

4.  Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function.

Authors:  Yejin Jang; Jin Soo Shin; Yi-Seul Yoon; Yun Young Go; Hye Won Lee; Oh Seung Kwon; Sehee Park; Man-Seong Park; Meehyein Kim
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

5.  Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells.

Authors:  Anup Kumar Singh; Ayushi Verma; Akhilesh Singh; Rakesh Kumar Arya; Shrankhla Maheshwari; Priyank Chaturvedi; Mushtaq Ahmad Nengroo; Krishan Kumar Saini; Achchhe Lal Vishwakarma; Kavita Singh; Jayanta Sarkar; Dipak Datta
Journal:  Epigenetics       Date:  2020-07-08       Impact factor: 4.528

Review 6.  Cancer Stem Cells and Neovascularization.

Authors:  Fengkai Li; Jiahui Xu; Suling Liu
Journal:  Cells       Date:  2021-04-30       Impact factor: 6.600

7.  Salinomycin triggers prostate cancer cell apoptosis by inducing oxidative and endoplasmic reticulum stress via suppressing Nrf2 signaling.

Authors:  Jianyong Yu; Yang Yang; Shan Li; Peng Meng
Journal:  Exp Ther Med       Date:  2021-07-01       Impact factor: 2.447

8.  Combined Anticancer Effect of Plasma-Activated Infusion and Salinomycin by Targeting Autophagy and Mitochondrial Morphology.

Authors:  Takashi Ando; Manami Suzuki-Karasaki; Miki Suzuki-Karasaki; Jiro Ichikawa; Toyoko Ochiai; Yukihiro Yoshida; Hirotaka Haro; Yoshihiro Suzuki-Karasaki
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

9.  Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models.

Authors:  Alicja Urbaniak; Megan R Reed; Daniel Fil; Anika Moorjani; Sarah Heflin; Michał Antoszczak; Michał Sulik; Adam Huczyński; Michalina Kupsik; Robert L Eoff; Melanie C MacNicol; Timothy C Chambers; Angus M MacNicol
Journal:  Biomed Pharmacother       Date:  2021-06-12       Impact factor: 7.419

10.  Epidermal growth factor receptor aptamer-conjugated polymer-lipid hybrid nanoparticles enhance salinomycin delivery to osteosarcoma and cancer stem cells.

Authors:  Zuochong Yu; Fangyi Chen; Xiaoxia Qi; Yinmei Dong; Yingying Zhang; Zhe Ge; Guoping Cai; Xinchao Zhang
Journal:  Exp Ther Med       Date:  2017-11-27       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.